Diabetes Mellitus type 2 affects over 200 million individuals worldwide. While DM2 has a strong familial component, the search for individual causative genes has been only mildly fruitful and development of DM2 is thought to depend on the combination of a number of genetic and environmental factors. With the cost for whole- genome sequencing of individuals in reach as well as the maturation of technologies for quantifiably measuring tens of thousands of biomolecules, there exists a tremendous opportunity to understand the genetic and bimolecular factors which underlie the progression to DM2. Our lab has recently developed a novel pipeline termed integrative personal omics profiling (iPOP) which combines genomic, transcriptomic, proteomic and metabolomics profiles with computational tools to comprehensively investigate the molecules and pathways that change during disease onset and progression. We propose to perform whole-genome sequencing and longitudinal iPOP analysis on a cohort of overweight individuals either high-risk or low-risk for progression to DM2. For this cohort, we will analyze blood samples at the onset of the study, after a moderate weight gain and after a period of significant weight loss. We hypothesize that through iPOP analysis we can elucidate novel molecular factors and pathways which change in response to weight gain and loss and which differ between high- and low-risk individuals. Through this analysis we will offer an unprecedented view of the changing molecular landscape underlying acquired insulin resistance.

Public Health Relevance

With the proposed research project, we seek to comprehensively profile the genomic and molecular changes that are associated with the progression to diabetes mellitus type 2 (DM2) in a cohort of individuals. This work represents the first step in developing personalized risk profiles for development of the disease. Such molecular portraits, in addition to furthering our understanding of how the disease develops in varied ways, will provide a significant public health benefit in identifying at-risk subjects for targeted intervention.

Agency
National Institute of Health (NIH)
Type
Postdoctoral Individual National Research Service Award (F32)
Project #
1F32DK100072-01A1
Application #
8717385
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Castle, Arthur
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Stanford University
Department
Genetics
Type
Schools of Medicine
DUNS #
City
Stanford
State
CA
Country
United States
Zip Code
94304